$3.86 Million NIH Grant Accelerates Purdue Veterinary Scholar’s Novel Approach in Race to Develop Effective Vaccine to Combat COVID-19

August 21, 2020

Suresh Mittal pictured standing in front of the Continuum sculpture outside Lynn Hall

In the midst of the COVID-19 pandemic, with many schools and colleges across the United States implementing plans to start face-to-face classroom teaching, the race to develop an effective vaccine is intensifying, according to Purdue University Distinguished Professor of Virology Suresh Mittal. “The availability of an effective vaccine will be vital to protect everyone here in the U.S. and worldwide,” said Dr. Mittal, who is an accomplished vaccine researcher in the College of Veterinary Medicine’s Department of Comparative Pathobiology.

COVID-19 is caused by a coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Dr. Mittal is leading a research team that is taking a novel approach to developing an efficient vaccine for COVID-19, and the research just received a major boost in the form of a five-year $3.86 million grant from the National Institutes of Health.

Dr. Mittal’s approach utilizes a harmless form of a common cold-like adenovirus as a vaccine platform. “This platform-based vaccine expresses the important SARS-CoV-2 immunogens that produce an immune response,” Dr. Mittal said. “This type of COVID-19 vaccine provides a balanced antibody and cell-based protection.”

Dr. Mittal said the COVID-19 vaccine needs to be highly immunogenic because the human immune system does not have an immune memory against this new virus. His vaccine approach is simple due to the use of a safe version of adenovirus with the capability to induce protective immune responses.

Dr. Mittal is collaborating on the research with Dr. Suresh Kuchipudi, clinical professor and associate director of the Animal Diagnostic Laboratory at Pennsylvania State University; and Dr. Suryaprakash Sambhara, Immunology Laboratory team lead at the Influenza Division of the Centers for Disease Control and Prevention.

Dr. Mittal emphasized that it will be critical to have several vaccine approaches in order to meet global demand for the COVID-19 vaccine. He said at present, there are at least three adenovirus-based COVID-19 vaccines in Phase 2 or 3 clinical trials. More than 160 COVID-19 vaccines are at various stages of development.

Dr. Mittal also cautions that the elderly are the most vulnerable segment of the population because of a higher risk of COVID-19 severity, and therefore, vaccine development efforts should consider the decline in the immune competence of the elderly.

“An effective COVID-19 vaccine will flatten the COVID-19 pandemic’s trajectory and its second wave, thus saving lives and the global economy,” Dr. Mittal said.

Writer(s): Kevin Doerr | pvmnews@purdue.edu

Recent Stories

“Paws Up” for Jennifer Danaher – brought to you by the PVM Wellness Committee

This week we express our gratitude to Jennifer Danaher, who is department secretary for Veterinary Clinical Sciences.

‘Purdue Pursuits’: A PVM angle on Purdue’s teaching and learning reading groups

Crafting meaningful and engaging course experiences has been at the top of Dielson Vieira’s mind ever since he joined the Purdue University College of Veterinary Medicine’s faculty in 2024. As a clinical assistant professor in the Department of Basic Medical Sciences, Vieira is already adept at applying innovative teaching practices to classroom environments, but that doesn’t stop him from seeking out new ideas, approaches and perspectives — insights he gains through outlets like Purdue’s teaching and learning reading groups.

Top tier biology journal publishes PVM study that unlocks secrets of a drug-resistant fungal pathogen, which causes serious infections in humans

Though the name “Candida auris” is far from a household term, public health experts know it well because the multi-drug-resistant fungal pathogen, which causes serious human infections, has been classified as an urgent threat by the U.S. Centers for Disease Control and Prevention (CDC) Antibiotic Threats Report (2019). Dr. Shankar Thangamani, Associate Professor of Microbiology and University Faculty Scholar in the Purdue University College of Veterinary Medicine’s Department of Comparative Pathobiology, is researching C. auris, aided by a 2.4 million grant from the National Institutes of Health (NIH). New research findings, just published in Nature Microbiology, show how C. auris adapts and evades the immune system.

In Print: ‘Translational Research Methods for Tauopathies’

A just-published 300-page volume edited by Jessica Fortin, Purdue assistant professor in the College of Veterinary Medicine’s Department of Basic Medical Sciences, provides a significant new resource for researchers studying a group of neurodegenerative diseases known as tauopathies. “Translational Research Methods for Tauopathies” provides detailed protocols intentionally selected to serve as a basis for research laboratories seeking to further treatments for such debilitating neurodegenerative diseases as Alzheimer’s and chronic traumatic encephalopathy (CTE).

It’s Almost Here!

Though the annual Purdue Veterinary Conference is almost upon us, there’s still time to register and take advantage of this time-honored College of Veterinary Medicine fall tradition that combines excellent continuing education with fun opportunities for reconnecting with colleagues and classmates, networking, and learning about the latest veterinary trends and products. The 2026 Purdue Veterinary Conference takes place September 23–26 on the Purdue University campus. The annual event has something for everyone, from veterinarians to veterinary technicians, faculty, staff and students.